全文获取类型
收费全文 | 70129篇 |
免费 | 5384篇 |
国内免费 | 340篇 |
专业分类
耳鼻咽喉 | 710篇 |
儿科学 | 1990篇 |
妇产科学 | 1678篇 |
基础医学 | 8758篇 |
口腔科学 | 1590篇 |
临床医学 | 7060篇 |
内科学 | 15741篇 |
皮肤病学 | 977篇 |
神经病学 | 5565篇 |
特种医学 | 2183篇 |
外国民族医学 | 2篇 |
外科学 | 10947篇 |
综合类 | 1209篇 |
现状与发展 | 1篇 |
一般理论 | 105篇 |
预防医学 | 5794篇 |
眼科学 | 1993篇 |
药学 | 4880篇 |
2篇 | |
中国医学 | 145篇 |
肿瘤学 | 4523篇 |
出版年
2023年 | 299篇 |
2022年 | 408篇 |
2021年 | 1257篇 |
2020年 | 802篇 |
2019年 | 1126篇 |
2018年 | 1375篇 |
2017年 | 950篇 |
2016年 | 1064篇 |
2015年 | 1271篇 |
2014年 | 1957篇 |
2013年 | 3036篇 |
2012年 | 4105篇 |
2011年 | 4477篇 |
2010年 | 2565篇 |
2009年 | 2366篇 |
2008年 | 4359篇 |
2007年 | 4517篇 |
2006年 | 4346篇 |
2005年 | 4462篇 |
2004年 | 4148篇 |
2003年 | 3739篇 |
2002年 | 3691篇 |
2001年 | 950篇 |
2000年 | 860篇 |
1999年 | 897篇 |
1998年 | 814篇 |
1997年 | 675篇 |
1996年 | 587篇 |
1995年 | 576篇 |
1994年 | 522篇 |
1993年 | 520篇 |
1992年 | 699篇 |
1991年 | 680篇 |
1990年 | 558篇 |
1989年 | 562篇 |
1988年 | 520篇 |
1987年 | 503篇 |
1986年 | 461篇 |
1985年 | 547篇 |
1984年 | 515篇 |
1983年 | 476篇 |
1982年 | 586篇 |
1981年 | 485篇 |
1980年 | 515篇 |
1979年 | 358篇 |
1978年 | 364篇 |
1977年 | 366篇 |
1976年 | 309篇 |
1975年 | 336篇 |
1974年 | 287篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Objective
The aim of the study was to estimate the effect of the state-based reinsurance programs through the section 1332 State Innovation Waivers on health insurance marketplace premiums and insurer participation.Data Source
2015 to 2022 Robert Wood Johnson Foundation Health Insurance Exchange Compare Datasets.Study Design
An event study difference-in-differences (DD) model separately for each year of implementation and a synthetic control method (SCM) are used to estimate year-by-year effects following program implementation.Data Collection/Extraction Methods
Not applicable.Principal Findings
Reinsurance programs were associated with a decline in premiums in the first year of implementation by 10%–13%, 5%–19%, and 11%–17% for bronze, silver, and gold plans (p < 0.05). There is a trend of sustained declines especially for states that implemented their programs in 2019 and 2020. The SCM analyses suggest some effect heterogeneity across states but also premium declines across most states. There is no evidence that reinsurance programs affected insurer participation.Conclusion
State-based reinsurance programs have the potential to improve the affordability of health insurance coverage. However, reinsurance programs do not appear to have had an effect on insurer participation, highlighting the need for policy makers to consider complementary strategies to encourage insurer participation. 相似文献2.
Rajendrababu Sharmila Puthuran George Varghese Alia Laxmi Ananya Uduman Mohammed Sithiq Wijesinghe Hiruni Kaushalya 《International ophthalmology》2022,42(8):2609-2618
International Ophthalmology - To investigate the efficacy and safety of non-valved Aurolab aqueous drainage implant (AADI) surgery combined with phacoemulsification in eyes with refractory glaucoma... 相似文献
3.
4.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献
5.
6.
7.
8.
9.